Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Gw Pharma ADR (GWPH)

Gw Pharma ADR (GWPH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,651,820
  • Shares Outstanding, K 31,047
  • Annual Sales, $ 527,210 K
  • Annual Income, $ -58,130 K
  • 60-Month Beta 1.98
  • Price/Sales 12.65
  • Price/Cash Flow N/A
  • Price/Book 9.08
Trade GWPH with:

Options Overview

Details
  • Implied Volatility 12.63%
  • Historical Volatility 129.30%
  • IV Percentile 3%
  • IV Rank 1.32%
  • IV High 118.29% on 03/16/20
  • IV Low 11.22% on 02/04/21
  • Put/Call Vol Ratio 0.51
  • Today's Volume 134
  • Volume Avg (30-Day) 2,003
  • Put/Call OI Ratio 0.62
  • Today's Open Interest 5,342
  • Open Int (30-Day) 11,861

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate -0.22
  • Number of Estimates 3
  • High Estimate 0.08
  • Low Estimate -0.60
  • Prior Year -0.24
  • Growth Rate Est. (year over year) +8.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
141.41 +51.51%
on 02/02/21
217.50 -1.49%
on 02/03/21
+64.02 (+42.61%)
since 01/26/21
3-Month
110.61 +93.70%
on 01/04/21
217.50 -1.49%
on 02/03/21
+86.64 (+67.89%)
since 11/25/20
52-Week
67.98 +215.17%
on 03/17/20
217.50 -1.49%
on 02/03/21
+107.25 (+100.23%)
since 02/26/20

Most Recent Stories

More News
GW Pharmaceuticals receives positive CHMP opinion for EPIDYOLEX(R) (cannabidiol) for use as treatment of seizures associated with Tuberous Sclerosis Complex

GW Pharmaceuticals plc (Nasdaq: GWPH) ("GW", "the Company" or "the Group"), a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines, today announces that the...

GWPH : 214.25 (-0.28%)
Legal Cannabis Market Price Trends 2020, Industry Analysis, Growth, Share and Forecast To 2027

Japan, Japan, Thu, 25 Feb 2021 01:42:46 / Comserve Inc. / -- Competitive Analysis: Aurora Cannabis, Canopy Growth Corporation, Maricann Group, Inc., GW Pharmaceuticals, plc., Aphria, Inc., Tilray, The...

APHA : 17.84 (-2.09%)
ACB.TO : 13.46 (-1.39%)
GWPH : 214.25 (-0.28%)
MRRCF : 0.0300 (+9.09%)
SHAREHOLDER ALERT: WeissLaw LLP Reminds LACQ, GWPH, PRSP, and CMD Shareholders About Its Ongoing Investigations

, /PRNewswire/ --

LACQ : 14.09 (+7.56%)
GWPH : 214.25 (-0.28%)
PRSP : 29.20 (+0.21%)
CMD : 74.28 (+1.21%)
Jazz Pharma (JAZZ) Q4 Earnings Miss, 2021 Sales View Dull

Jazz Pharmaceuticals (JAZZ) reports mixed fourth-quarter 2020 results as earnings miss estimates while sales beat the same. Shares down.

JAZZ : 168.04 (-1.58%)
USNA : 97.06 (+0.65%)
GWPH : 214.25 (-0.28%)
SAVA : 48.58 (-4.52%)
INVESTIGATION ALERT: Halper Sadeh LLP Investigates AEGN, FFG, NK, GWPH; Shareholders Are Encouraged to Contact the Firm

NEW YORK, NY / ACCESSWIRE / February 20, 2021 / Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies:

AEGN : 25.85 (-0.19%)
FFG : 57.04 (-0.37%)
NK : 32.51 (-4.89%)
GWPH : 214.25 (-0.28%)
Should You Invest in Marijuana Stocks & ETFs Now?

CNBC's cannabis expert Tim Seymour discusses the outlook for the industry.

JAZZ : 168.04 (-1.58%)
GWPH : 214.25 (-0.28%)
CGC : 32.75 (-1.39%)
APHA : 17.84 (-2.09%)
MJ : 22.56 (-1.27%)
TLRY : 24.36 (-0.57%)
YOLO : 25.09 (+0.20%)
VFF : 15.79 (+4.09%)
THCX : 19.77 (-1.98%)
POTX : 16.53 (-2.99%)
TOKE : 20.40 (-2.16%)
CNBS : 30.12 (-2.02%)
SHAREHOLDER ALERT: WeissLaw LLP Reminds EGOV, GRNV, LACQ, and GWPH Shareholders About Its Ongoing Investigations

, /PRNewswire/ --

EGOV : 34.71 (+0.46%)
TYL : 463.42 (+0.46%)
GRNV : 10.18 (+0.20%)
LACQ : 14.09 (+7.56%)
GWPH : 214.25 (-0.28%)
INVESTIGATION ALERT: Halper Sadeh LLP Investigates the Following Companies on Behalf of Shareholders - PTVCA, AEGN, CATM, CHNG, GWPH, PS, SNCA

, /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

PTVCA : 22.91 (-0.22%)
AEGN : 25.85 (-0.19%)
CATM : 38.55 (-0.16%)
CHNG : 22.87 (-0.35%)
GWPH : 214.25 (-0.28%)
PS : 20.59 (-0.53%)
SNCA : 1.3400 (-4.29%)
Legal Marijuana Market size is expected to be more than USD 90.5 billion by 2027

Selbyville, Delaware According to the research report titled Legal Marijuana Market Size, Share, Trends, & Industry Analysis Report, By Product; By Distribution Channel; By Regions: Segment Forecast, 2020...

ACB.TO : 13.46 (-1.39%)
CBDS : 0.8400 (-2.83%)
GWPH : 214.25 (-0.28%)
CNAB : 0.0165 (-65.63%)
GW Pharmaceuticals plc Reports Fourth Quarter and Year-End 2020 Financial Results and Operational Progress

- Total revenue of $148.2 million for the fourth quarter and $527.2 million for the full year -

GWPH : 214.25 (-0.28%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and...

See More

Key Turning Points

3rd Resistance Point 216.62
2nd Resistance Point 216.02
1st Resistance Point 215.13
Last Price 214.25
1st Support Level 213.64
2nd Support Level 213.04
3rd Support Level 212.15

See More

52-Week High 217.50
Last Price 214.25
Fibonacci 61.8% 160.38
Fibonacci 50% 142.74
Fibonacci 38.2% 125.10
52-Week Low 67.98

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar